# To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination

> **NCT05737771** · PHASE1 · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 40 (estimated)

## Conditions studied

- FDC
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** DWC202213
- **DRUG:** DWJ1563
- **DRUG:** DWP16001

## Key facts

- **NCT ID:** NCT05737771
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-25
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05737771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05737771, "To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05737771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*